Cogent Biosciences (COGT) Return on Capital Employed (2018 - 2026)
Cogent Biosciences (COGT) posted quarterly Return on Capital Employed of 41.98% for Q1 2026, up 7047.0% year-over-year from 0.59% in Q1 2025, and up 22.19% quarter-over-quarter from 53.96% in Q4 2025.
Cogent Biosciences (COGT) Return on Capital Employed (2018 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Return on Capital Employed for 9 consecutive years, with 41.98% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 7047.0% year-over-year to 41.98%; the TTM figure through Mar 2026 stood at 41.98% (up 7047.0% YoY), while the FY2025 annual figure was 58.61%, up 4554.0% from the prior year.
- Return on Capital Employed rose to 41.98% in Q1 2026 per COGT's latest filing, from 53.96% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 39.89% in Q3 2022 and bottomed at 135.66% in Q2 2025.
- Historically, Return on Capital Employed has averaged 68.55% across 5 years, with a median of 59.22% in 2024.
- Annual changes were most pronounced in 2025 — Return on Capital Employed tumbled 7644 bps — and 2026, when it soared 7047 bps.
- Cogent Biosciences' Return on Capital Employed stood at 51.1% in 2022, then plunged by 37 bps to 70.25% in 2023, then tumbled by 31 bps to 91.9% in 2024, then jumped by 41 bps to 53.96% in 2025, then climbed by 22 bps to 41.98% in 2026.
- Business Quant data shows COGT's Return on Capital Employed at 41.98% in Q1 2026, 53.96% in Q4 2025, and 106.76% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | -48.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.07% |
| Mar 31, 2026 | -41.98% |
| Dec 31, 2025 | -53.96% |
| Sep 30, 2025 | -106.76% |
| Jun 30, 2025 | -135.66% |
| Mar 31, 2025 | -112.45% |
| Dec 31, 2024 | -91.90% |
| Sep 30, 2024 | -73.58% |
| Jun 30, 2024 | -59.22% |
| Mar 31, 2024 | -63.48% |
| Dec 31, 2023 | -70.25% |
| Sep 30, 2023 | -57.09% |
| Jun 30, 2023 | -56.58% |
| Mar 31, 2023 | -61.20% |
| Dec 31, 2022 | -51.10% |
| Sep 30, 2022 | -39.89% |
| Jun 30, 2022 | -43.56% |
| Mar 31, 2022 | -46.71% |
| Dec 31, 2021 | -36.56% |
| Sep 30, 2021 | -29.90% |